We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients with Metastatic Castration-resistant Prostate Cancer
Previous Study | Return to List | Next Study

A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02705469
First Posted: March 10, 2016
Last Update Posted: November 20, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Zenith Epigenetics
  Purpose
This is an open label, Phase 1, dose escalation and dose confirmation study of ZEN003694 in patients with mCRPC.

Condition Intervention Phase
Metastatic Castration-Resistant Prostate Cancer Drug: ZEN003694 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer

Resource links provided by NLM:


Further study details as provided by Zenith Epigenetics:

Primary Outcome Measures:
  • For dose escalation only: Incidence of dose-limiting toxicities (DLT) [ Time Frame: Cycle 1 (Day 1 thru Day 28) ]
    A DLT is a treatment-related, clinically significant adverse event or laboratory abnormality occurring during the first cycle of treatment (Day 1 thru Day 28).

  • For dose escalation and dose confirmation: Incidence of treatment-related adverse events (AE) and treatment-related serious adverse events (SAE) [ Time Frame: Up to 24 months ]

Secondary Outcome Measures:
  • Measure the pharmacokinetic (PK) parameter: AUC of ZEN003694 [ Time Frame: Cycle 1 Day 1: pre-dose, 0.25, 0.5, 1, 2, 4, 6 and 8 hours post-dose; Cycle 1 Day 2: pre-dose; Cycle 1 Day 15: pre-dose, 0.25, 0.5, 1, 2, 4, 6 and 8 hours post-dose; Cycle 2 Day 1: pre-dose ]
    AUC is defined as the area under the curve (plasma concentration of drug over time).

  • Measure the PK parameter: Cmax of ZEN003694 [ Time Frame: Cycle 1 Day 1: pre-dose, 0.25, 0.5, 1, 2, 4, 6 and 8 hours post-dose; Cycle 1 Day 2: pre-dose; Cycle 1 Day 15: pre-dose, 0.25, 0.5, 1, 2, 4, 6 and 8 hours post-dose; Cycle 2 Day 1: pre-dose ]
    Cmax is defined as maximum or peak plasma concentration of drug.

  • Measure the PK parameter: Cmin of ZEN003694 [ Time Frame: Cycle 1 Day 1: pre-dose, 0.25, 0.5, 1, 2, 4, 6 and 8 hours post-dose; Cycle 1 Day 2: pre-dose; Cycle 1 Day 15: pre-dose, 0.25, 0.5, 1, 2, 4, 6 and 8 hours post-dose; Cycle 2 Day 1: pre-dose ]
    Cmin is defined as minimum or trough plasma concentration of drug.

  • Measure the PK parameter: Tmax of ZEN003694 [ Time Frame: Cycle 1 Day 1: pre-dose, 0.25, 0.5, 1, 2, 4, 6 and 8 hours post-dose; Cycle 1 Day 2: pre-dose; Cycle 1 Day 15: pre-dose, 0.25, 0.5, 1, 2, 4, 6 and 8 hours post-dose; Cycle 2 Day 1: pre-dose ]
    Tmax is defined as the time from dosing to the maximum plasma concentration.

  • Measure the PK parameter: t1/2 of ZEN003694 [ Time Frame: Cycle 1 Day 1: pre-dose, 0.25, 0.5, 1, 2, 4, 6 and 8 hours post-dose; Cycle 1 Day 2: pre-dose; Cycle 1 Day 15: pre-dose, 0.25, 0.5, 1, 2, 4, 6 and 8 hours post-dose; Cycle 2 Day 1: pre-dose ]
    t/12 is defined as the half-life of drug.

  • Evaluate prostate-specific antigen (PSA) response rate by PCWG2 criteria [ Time Frame: From screening up to 24 months ]
  • Evaluate radiographic response rate by PCWG2 criteria [ Time Frame: From screening up to 24 months ]
  • Evaluate median progression-free survival by PCWG2 criteria [ Time Frame: From screening up to 24 months ]
  • Evaluate circulating tumor cell (CTC) response rate during dose confirmation phase only [ Time Frame: From screening up to 12 months ]

Estimated Enrollment: 44
Actual Study Start Date: May 2016
Study Completion Date: October 2017
Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dose Escalation and Dose Confirmation - ZEN003694 Single Agent
ZEN003694 will be administered orally as a single agent once daily in 28-day cycles, enrolling mCRPC patients.
Drug: ZEN003694

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males age ≥ 18 years
  2. Metastatic, castrate resistant, histologically confirmed prostate cancer; surgically castrated or continuous medical castration for ≥ 8 weeks prior to screening
  3. Serum testosterone < 50 ng/dL determined within 4 weeks of first administration of study drug
  4. Prior progression on one or more androgen-receptor/androgen-synthesis inhibitor therapies (e.g. abiraterone, enzalutamide, apalutamide, TAK-700 and/or galeterone) by Prostate Cancer Working Group 2 (PCWG2) criteria. Prior progression on bicalutamide/nilutamide/flutamide/ketoconazole alone is not allowed.
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  6. Adequate laboratory parameters [absolute neutrophil (ANC), platelets, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, creatinine and coagulation parameters] at screening

Exclusion Criteria:

  1. Any history of brain metastases or prior seizure or conditions predisposing to seizure activity
  2. Have previously received an investigational BET inhibitor (including previous participation in this study or Study ZEN003694-002)
  3. Have received prior systemic anti-cancer therapy or investigational therapy within 2 weeks or five half-lives, whichever is shorter, prior to the first administration of study drug
  4. Failure to recover to Grade 1 or lower toxicity related to prior systemic therapy (excluding alopecia and neuropathy) prior to study entry
  5. Radiation therapy within 2 weeks of first administration of study drug
  6. Have received prior chemotherapy in the metastatic castration-resistant setting (prior chemotherapy in the hormone-sensitive setting is allowed provided last dose was at least 6 months prior to study entry)
  7. Currently receiving medications known to be strong inducers or inhibitors of CYP3A4 with a narrow therapeutic window. Strong inducers and inhibitors of CYP3A4 with narrow therapeutic ranges must be discontinued at least 7 days prior to the first administration of study drug.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02705469


Locations
United States, California
University of California Los Angeles Medical Center
Los Angeles, California, United States
University of California San Francisco Medical Center
San Francisco, California, United States
United States, Michigan
Karmanos Cancer Institute
Detroit, Michigan, United States
Karmanos Cancer Institute
Farmington Hills, Michigan, United States
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States
United States, Virginia
Virginia Oncology Associates
Hampton, Virginia, United States
Virginia Oncology Associates
Norfolk, Virginia, United States
Sponsors and Collaborators
Zenith Epigenetics
  More Information

Responsible Party: Zenith Epigenetics
ClinicalTrials.gov Identifier: NCT02705469     History of Changes
Other Study ID Numbers: ZEN003694-001
First Submitted: February 10, 2016
First Posted: March 10, 2016
Last Update Posted: November 20, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Zenith Epigenetics:
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase 1
Prostate Cancer
Pharmacokinetics (PK)
ZEN003694
ZEN-3694
Metastatic Castrate-Resistant Prostate Cancer
BET inhibitor (BETi)
Bromodomain
Pharmacodynamics (PD)
Epigenetics

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases